Methods
Ribavirin's serum concentration was measured in 20 HIV/ HCV co-infected patients who were eligible for HCV treatment 4 weeks after treatment commenced. A serum concentration of 2.2 microgram/ml is considered as therapeutic level. Dose of ribavirin was increased as 200 milligram daily (not more than 1,200 mg/day) in patients whose ribavirin serum concentration was less than 2.2 microgram/ml. Hemoglobin levels measured at first day of treatment and 3 months later.
Summary of results
Mean ribavirin serum concentration in 20 patients was 1.96 microgram/ml (R: 0.8-5.2). Seven of 20 (35%) of patients had a serum concentration of ribavirin more than 2.2 microgram/ml (mean: 3) while 13 of 20 patients (65%) had not achieved therapeutic level (mean: 1.4). Dose of ribavirin was increased in nine of 13. Nearly all (8/9) found an increase in serum concentration of ribavirin. 50% of them had achieved the therapeutic level (2.2 microgram/ml) while four patients, in spite of increased serum concentration of ribavirin, did not reach therapeutic level. Totally, 11 of 20 (55%) reached 2.2 while nine of 20 (45%) less than 2.2. Decreased hemoglobin level was observed nearly in all patients. Mean: 2 g/dl (range: -0.1-5.6). In patients who reached therapeutic level of ribavirin decreased Hb level was more important (mean: 2.3 g/dl) than patients who did not achieved 2.2 microgram/ml (mean: 1.6 g/dl). We did not find any correlation between ribavirin serum concentration and early virologic response nor sustained virologic response.
Conclusion
Increased dose of ribavirin leads to increase serum concentration of ribavirin. Along with increased serum concentration of ribavirin, the rate of decreased hemoglobin level increases.
